A New Chapter in Neuropsychiatry

Neuropsychiatric disorders remain among the most difficult diseases to treat in medicine.

Major depressive disorder alone affects hundreds of millions of people worldwide. Yet treatment options have changed surprisingly little over the decades, and many patients cycle through therapies that provide only partial or temporary relief.

Part of the challenge is scientific. The brain is extraordinarily complex, and historically, researchers have lacked the tools to study and influence its signaling pathways with precision.

But advances in neuroscience—and a deeper understanding of how neural circuits regulate mood and cognition—are opening new possibilities.

Canaan company, Draig Therapeutics, launched with $140 million in Series A financing to advance a new generation of medicines for neuropsychiatric disorders.

The financing brings together a strong syndicate of life sciences investors and positions the company to rapidly advance a pipeline of novel medicines targeting the underlying biology of brain disorders.

For years, neuroscience drug development faced skepticism from investors and the broader biotech ecosystem.

Clinical timelines are long, the brain remains difficult to study, and many past programs failed to translate promising biology into effective medicines.

But the scientific landscape has evolved.

Advances in molecular biology, imaging, and translational neuroscience are providing far clearer insight into the signaling pathways that govern brain function. That deeper understanding is enabling companies like Draig to pursue more precise and biologically grounded approaches to treating psychiatric disease.

The scale of Draig’s launch reflects growing confidence that the next generation of neuroscience companies will look very different from the last.

Many psychiatric medicines were originally discovered through observation rather than precise biological targeting. Draig’s approach starts from a different place: understanding the signaling systems that regulate how neurons communicate.

The company focuses on glutamate and GABA, two neurotransmitter systems that control the balance between excitatory and inhibitory activity in the brain. When that balance is disrupted, neural circuits involved in mood and cognition can become dysregulated.

Restoring that equilibrium—rather than broadly altering brain chemistry—has become an increasingly important strategy in neuroscience drug development.

Draig’s programs are designed to modulate these pathways with far greater selectivity than earlier generations of psychiatric medicines.

The company’s lead program, DT-101, is designed to modulate AMPA receptors, which play a central role in glutamate signaling and synaptic plasticity.

The therapy has already completed early clinical testing and is expected to move into Phase 2 trials in major depressive disorder.

In parallel, Draig is advancing additional programs targeting GABA receptors, expanding the potential to address a broader set of neuropsychiatric conditions.

Taken together, the pipeline reflects a broader shift underway in neuroscience: moving from generalized psychiatric drugs toward therapies designed to influence specific neural circuits.

Millions of people living with depression and other neuropsychiatric disorders still lack treatments that work reliably and sustainably.

Closing that gap will require both scientific progress and the ability to translate discovery into clinical medicines.

Draig Therapeutics represents a new effort to do exactly that—bringing together academic insight, drug discovery expertise, and long-term investment to advance a new class of brain therapies.

If successful, these efforts could help redefine how neuropsychiatric diseases are treated and open the door to a new era of precision medicine for the brain.